Biotinylated Human LILRB1 / CD85j / ILT2 Protein, Fc,Avitag™
分子别名(Synonym)
CD85J,LILRB1,CD85,ILT2,LIR1,MIR7
表达区间及表达系统(Source)
Biotinylated Human LILRB1, Fc,Avitag (CDJ-H82F7) is expressed from human 293 cells (HEK293). It contains AA Gly 24 - His 458 (Accession # D9IDM8-1).
Predicted N-terminus: Gly 24
蛋白结构(Molecular Characterization)
This protein carries a human IgG1 Fc tag at the C-terminus, followed by a Avi tag (Avitag™).
The protein has a calculated MW of 75.6 kDa. The protein migrates as 100-116 kDa under reducing (R) condition, and 150 kDa under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.
标记(Labeling)
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
蛋白标记度(Protein Ratio)
Passed as determined by the HABA assay / binding ELISA.
内毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
纯度(Purity)
>95% as determined by SDS-PAGE.
制剂(Formulation)
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景(Background)
LILRB1(Uniprot No.D9IDM8-1)是一种与NK细胞上LILRB1低表达相关的变体。它反映了LILRB1基因座的多样性及其对NK细胞表达模式的影响。LILRB1属于LIR受体的B亚家族,其包含两个或四个细胞外免疫球蛋白结构域、一个跨膜结构域和两到四个细胞质免疫受体酪氨酸基抑制基序(ITIM)。受体在免疫细胞上表达,与抗原呈递细胞上的MHC I类分子结合,并传递抑制免疫反应刺激的负信号。它被认为可以控制炎症反应和细胞毒性,以帮助集中免疫反应并限制自身反应性。
关键字: LILRB1;LILRB1蛋白;LILRB1重组蛋白;ACRO;百普赛斯;
百普赛斯集团ACROBiosystems Group(股票代码:301080)是成立于2010年的跨国生物科技公司,是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球,横跨亚洲、北美洲、欧洲,在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家,与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。